Melissa Baird Sells 67,687 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMSGet Free Report) COO Melissa Baird sold 67,687 shares of the stock in a transaction dated Wednesday, February 12th. The shares were sold at an average price of $44.71, for a total value of $3,026,285.77. Following the completion of the sale, the chief operating officer now owns 706,872 shares of the company’s stock, valued at approximately $31,604,247.12. This trade represents a 8.74 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Melissa Baird also recently made the following trade(s):

  • On Tuesday, January 21st, Melissa Baird sold 67,687 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.35, for a total value of $1,986,613.45.
  • On Tuesday, December 10th, Melissa Baird sold 85,561 shares of Hims & Hers Health stock. The shares were sold at an average price of $31.01, for a total value of $2,653,246.61.
  • On Monday, November 18th, Melissa Baird sold 58,750 shares of Hims & Hers Health stock. The shares were sold at an average price of $21.04, for a total value of $1,236,100.00.

Hims & Hers Health Trading Up 2.1 %

Shares of NYSE HIMS opened at $60.41 on Friday. The company has a market cap of $13.20 billion, a price-to-earnings ratio of 137.31 and a beta of 1.35. Hims & Hers Health, Inc. has a 12-month low of $9.22 and a 12-month high of $64.84. The stock’s 50 day simple moving average is $32.06 and its 200 day simple moving average is $24.28.

Institutional Trading of Hims & Hers Health

Hedge funds have recently made changes to their positions in the stock. Main Management ETF Advisors LLC bought a new stake in shares of Hims & Hers Health in the 3rd quarter worth approximately $672,000. Robeco Institutional Asset Management B.V. acquired a new stake in Hims & Hers Health in the 3rd quarter valued at approximately $604,000. Royce & Associates LP increased its position in Hims & Hers Health by 17.0% in the 3rd quarter. Royce & Associates LP now owns 341,000 shares of the company’s stock valued at $6,281,000 after acquiring an additional 49,500 shares during the period. Versor Investments LP acquired a new stake in Hims & Hers Health in the 3rd quarter valued at approximately $634,000. Finally, International Assets Investment Management LLC acquired a new stake in Hims & Hers Health in the 3rd quarter valued at approximately $6,790,000. Institutional investors own 63.52% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently commented on HIMS shares. TD Cowen reissued a “buy” rating and issued a $28.00 price target on shares of Hims & Hers Health in a report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft increased their price target on Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a report on Wednesday, November 6th. Citigroup downgraded Hims & Hers Health from a “neutral” rating to a “sell” rating and increased their price target for the company from $24.00 to $25.00 in a report on Friday, January 10th. Piper Sandler increased their price target on Hims & Hers Health from $21.00 to $24.00 and gave the company a “neutral” rating in a report on Monday, January 6th. Finally, Morgan Stanley started coverage on Hims & Hers Health in a report on Tuesday, December 17th. They issued an “overweight” rating and a $42.00 price target for the company. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $25.13.

Read Our Latest Stock Analysis on HIMS

About Hims & Hers Health

(Get Free Report)

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Further Reading

Insider Buying and Selling by Quarter for Hims & Hers Health (NYSE:HIMS)

Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.